Introduction
Neoadjuvant chemotherapy is a standard of care option for bulky, but potentially resectable, nonesmall-cell lung cancers (NSCLCs). 1 Although major pathologic response (<10% viable tumor cells) and pathologic complete response (pCR) to neoadjuvant chemotherapy are uncommon they are associated with improved overall survival. 2 It is unknown whether neoadjuvant treatment with a targeted therapy can lead to similar or improved outcomes, potentially with reduced toxicity. Hepatocyte growth factor receptor (MET) exon 14 skipping (METex14) mutations predict response to MET tyrosine kinase inhibitors (TKIs) in the metastatic disease setting. 3 Herein, we describe a patient with locally-advanced METex14-mutated lung adenocarcinoma who experienced dramatic clinical benefit and pCR after neoadjuvant treatment with crizotinib.
Case
A 59-year-old Asian woman presented with cough and chest pain, and was found to have an unresectable 15-cm right upper lobe lung mass with multiple enlarged mediastinal lymph nodes and tiny right-sided pleural nodules of uncertain significance (Figure 1 ). An endobronchial ultrasound-guided fine needle aspiration of a station 4R lymph node showed lung adenocarcinoma ( Figure 2A ). Clinical next-generation sequencing of tumor tissue (FoundationOne, Foundation Medicine, Cambridge, MA) and plasma cell-free DNA (Guardant360, Guardant Health Inc, Redwood City, CA) identified a METex14 mutation (Figure 1 ).
The patient was treated with the MET TKI crizotinib (250 mg twice daily), which resulted in a 60% decrease in size of the primary right upper lobe lesion and resolution of previously identified small right pleural nodules in computed tomography (CT) chest imaging that was obtained after 2 months of treatment. Hypermetabolism of the primary lesion was reduced and there was resolution of hypermetabolic mediastinal lymph adenopathy on subsequent fluorine-18 fluorodeoxyglucose (F18-FDG) positron emission tomography (PET)/CT at 18 weeks of treatment ( Figure 1) . A biopsy of the residual right upper lobe lesion at 3 months of treatment showed only necrotic debris and the METex14 mutation was no longer detectable in plasma.
After 8 months of crizotinib treatment with sustained radiologic response the patient underwent a right-sided pneumonectomy with mediastinal lymph node dissection for resection of her residual right lung mass. Pathology review of her pneumonectomy specimen showed fibrosis and macrophage accumulation with only necrotic, nonviable tumor cells identified, consistent with pCR ( Figure 2B ). She recovered well postoperatively without significant functional limitations and resumed crizotinib treatment 1 week postoperatively
Clinical Practice Points
Hepatocyte growth factor receptor (MET) exon 14 (METex14) skipping mutations are an emerging therapeutic target in nonesmall-cell lung cancer. Neoadjuvant treatment with the MET tyrosine kinase inhibitor crizotinib in a locally advanced, unresectable METex14-mutated lung adenocarcinoma led to conversion to resectable status with pathologic complete response. Neoadjuvant treatment with targeted therapies might provide an alternative to neoadjuvant chemotherapy for patients with oncogenic driver mutations.
with good tolerance to therapy. There was no evidence of recurrent disease at 6 months of follow-up after surgery.
Discussion
Neoadjuvant chemotherapy plays an established role within the standard of care for locally advanced NSCLC, offering the potential to convert borderline resectable to resectable disease and to limit the morbidity of definitive local therapy. A meta-analysis showed improvement in 5-year overall survival (45% vs. 40%) for patients with resectable stage IB/IIIA disease who received neoadjuvant therapy. 4 Although this overall improvement in survival is of limited magnitude, the presence of a major pathological response to Neoadjuvant Crizotinib in METex14 Positive NSCLC neoadjuvant chemotherapy, defined as <10% viable tumor cells on pathology review of the resection specimen, is strongly predictive for improved overall survival (85% vs. 40% 5-year overall survival; P < .0001). 5 The role of neoadjuvant targeted therapy or immunotherapy in NSCLC is less well established. Early reports describing the use of these classes of therapy in the neoadjuvant setting, measured according to pathologic response rates, suggest potential for clinical benefit as well as acceptable safety profiles. In a series of 7 patients with operable epidermal growth factor receptor (EGFR)-mutated NSCLC treated with a neoadjuvant EGFR TKI, <50% residual viable tumor was seen in 3 patients, in 2 of whom there was <5% viable tumor. 6 A near-complete response to neoadjuvant crizotinib was reported in a patient with anaplastic lymphoma kinase (ALK)-rearranged NSCLC after disease progression during an initial trial of neoadjuvant platinum-based chemotherapy. 7 The neoadjuvant role of immunotherapy has also been evaluated. In a pilot study of 21 patients a major pathologic response rate was seen in 45% of patients treated with neoadjuvant nivolumab. As described in this case, the radiographic response rate (10% partial radiographic response) underestimated the pathologic response rate. 6 A similar discordance between radiographic response rates (0% overall response rate according to Response Evaluation Criteria in Solid Tumors criteria) and pathologic response rates (21% major pathologic response rate) was seen in a study that evaluated the use of neoadjuvant atezolizumab in patients with resectable NSCLC. 8 For metastatic NSCLC response rates to targeted therapy are higher than those seen with first-line platinum-based chemotherapy, and associated with improved overall survival. 9 In the neoadjuvant setting, radiographic response rates of 35.4% and 53.3%, and pCR rates of 4% and 10.5% have been reported to gemcitabine/cisplatin and carboplatin/paclitaxel, respectively. 10, 11 In comparison, radiographic response rates of 80% and higher have been reported to first-line treatment with the EGFR and ALK TKIs osimertinib and alectinib in the setting of EGFR-mutated or ALK-rearranged metastatic disease. 12, 13 Although there is currently no US Food and Drug Administration-approved MET TKI for use in METex14-mutated NSCLC, an unconfirmed response rate of up to 44% has been reported in an earlier-phase study. 14 merestinib (NCT02920996), and savolitinib (NCT02897479). In combination with a favorable side effect profile, neoadjuvant targeted therapy might be a reasonable option for patients with lung cancers that harbor a targetable oncogene, with lower predicted toxicity and higher response rates than the platinum-based chemotherapy typically used for neoadjuvant therapy.
Conclusion
The response to neoadjuvant crizotinib in MET exon 14-mutated NSCLC described herein converted an unresectable tumor to one in which a complete R0 resection was possible. Importantly, the surgical pathology showed complete pathological response (Figure 2 ) despite persistent residual right lung mass hypermetabolism on F18-FDG PET/CT imaging. This pattern mirrors findings from recent studies of neoadjuvant checkpoint inhibitors, 6, 8 in which the degree of radiographic response underestimated pathologic response rates. The case highlights the need for prospective studies to evaluate the role of precision medicine-based, molecularly targeted anticancer therapies in the neoadjuvant setting. 17 Such prospective studies are the subject of ongoing clinical trials (Table 1) , including those evaluating osimertinib (NCT03433469) and crizotinib (NCT03088930) in EGFR-mutated and MET/ALK/ROS protooncogene 1, receptor tyrosine kinase (ROS1)-altered, surgically resectable NSCLC. 
